Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting

BMC Medicine

Commentary

Anna Maria Frezza¹  Silvia Stacchiotti¹  Alessandro Gronchi² 

[1] Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy;

关键词: Sarcoma;    Gastrointestinal stromal tumours;    Prognostic assessment;    Preoperative treatment;    Chemotherapy;    Antiangiogenic drugs;    Immunotherapy;    Next generation sequencing;   

DOI  :  10.1186/s12916-017-0931-4

 received in 2017-08-03, accepted in 2017-08-11,  发布年份 2017

来源: Springer

【 摘 要 】

Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.

【 授权许可】

CC BY   
© The Author(s). 2017